Key result
Alteplase administration for acute ischemic stroke caused a ≥0.4-point INR increase in 16.9% of patients, with African American race being an independent predictor (OR 3.48; 95% CI 1.5-7.6; P=0.002).
Why the study?
Alteplase may elevate INR results, but the exact rate of elevation occurrence is not firmly established in the literature.
Does alteplase administration cause an elevation in INR in patients with acute ischemic stroke?
Cohort (n=261)
Yes
Does alteplase administration cause an elevation in INR in patients with acute ischemic stroke?
Alteplase administration for acute ischemic stroke is associated with a ≥0.4-point increase in INR in 16.9% of patients, with African American race being an independent predictor of this elevation.
INR elevation after alteplase warrants monitoring in stroke patients; observational data leave open bleeding implications and need for prospective confirmation.
Background/Objective: Alteplase may elevate international normalized ratio (INR) results, although the exact rate of elevation occurrence is not firmly established in the literature. The purpose of this study is to determine the occurrence rate of INR elevation following alteplase administration. We also aimed to determine what factors are independently associated with the development of elevated INR following alteplase administration for ischemic stroke. Methods: We conducted a multicenter, retrospective, cohort study of patients who received alteplase for acute ischemic stroke. Patients were screened for baseline INR measurement and a repeat value within 24 hours of alteplase administration. The primary outcome was the percent of patients who experienced ≥0.4-point increase in INR. Secondary outcomes included the rate of adverse bleeding events and identification of factors independently associated with elevated INR following alteplase administration. Results and Conclusions: Two hundred and sixty-one patients were included, with 44 (16.9%) patients having an INR increase of 0.4 or more. Patients with an INR increase ≥0.4 experienced a nonstatistically significant increase in bleeding episodes (8.8% vs 18.2%; P = .10). We identified African American race (odds ratio, 3.48, 95% confidence interval, 1.5-7.6; P = .002) as an independent predictor of INR increase ≥0.04. An INR elevation is common following receipt of alteplase for ischemic stroke. Those of African American race were at increased risk of INR elevation; however, more studies are needed to determine whether these patients are at a higher bleeding risk as a result of INR elevation.
No takes yet. Share an insight, caveat, or question.
Erdman et al. (2019) conducted a cohort in Acute ischemic stroke (n=261). Alteplase was evaluated on Percent of patients who experienced ≥0.4-point increase in INR. Alteplase administration for acute ischemic stroke caused a ≥0.4-point INR increase in 16.9% of patients, with African American race being an independent predictor (OR 3.48; 95% CI 1.5-7.6; P=0.002).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: